Latest Biotech News

Jason Beckwith, PhD, a biomanufacturing talent efficiency expert, warns of a potential 'talent singularity' by 2028 where demand for skilled biomanufacturing professionals will outstrip supply. He...

Caris Life Sciences published pioneering data validating its platform for minimal residual disease detection and early cancer identification with commercial launches anticipated soon....

Jazz Pharmaceuticals announced that current president and COO Renée Galá will succeed retiring CEO Bruce Cozadd on August 11. Separately, Bioptimus, QuidelOrtho, and Becton Dickinson made key...

Soleno Therapeutics reported stronger-than-expected sales growth for Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, with net revenues between $31 million and...

Research led by cardiologist Jürg Beer at the University of Zürich highlights the impact of aging gut microbiomes on vascular senescence. Elevated microbial metabolites phenylacetic acid (PAA) and...

The U.S. Food and Drug Administration has initiated a policy shift by publicly releasing over 200 complete response letters (CRLs) issued between 2020 and 2024 for drugs that were eventually...

Capricor Therapeutics has received a complete response letter from the U.S. FDA rejecting its biologics license application for deramiocel, an allogeneic cardiosphere-derived cell therapy intended...

Biopharma dealmaking reached a high point in June 2025, with total transaction value hitting $35.07 billion, marking the strongest month of the year. Among significant deals, Merck & Co. acquired...

Radiopharmaceutical developers Actithera and Nuclidium have attracted significant venture capital investments to advance clinical and manufacturing capabilities. Actithera closed a $75.5 million...

New AI-based tools are accelerating drug discovery and protein research by modeling complex biological processes with enhanced speed and accuracy. Microsoft Research unveiled BioEmu, a generative...

Emerging genomic and diagnostic technologies seek to improve early detection and monitoring of cancers. Personalis and Tempus AI expanded their collaboration to include colorectal cancer,...

The biomanufacturing industry is approaching a critical talent deficit projected around 2028, driven by growing demand for specialized skills outpacing supply. Jason Beckwith, PhD, of Merrill...

July 2025 has seen robust FDA approval activity with at least eight products awaiting decisions and multiple new drug entities (NMEs) approved in June, raising the 2025 tally to 19. Highlights...

Cutting-edge RNA and antibody therapies are emerging to address cardiovascular and allergic diseases. Shanghai Circode Biomed has advanced HM-2002, a circular RNA-based drug candidate for ischemic...

Jazz Pharmaceuticals appointed current COO Renée Galá as incoming CEO, succeeding co-founder Bruce Cozadd effective August 2025, signaling continuity amid operational shifts. Karyopharm...

The FDA has publicly released an initial batch of over 200 Complete Response Letters (CRLs) from 2020 to 2024, marking a significant policy shift aimed at increasing transparency in drug approval...

Merck completed a $10 billion acquisition of Verona Pharma to strengthen its cardiorespiratory portfolio with Ohtuvayre, a selective dual inhibitor targeting PDE3 and PDE4 enzymes, intended as a...

New AI models revolutionize understanding of protein dynamics and cellular gene networks, enhancing drug discovery and disease research. Microsoft Research developed BioEmu, a generative deep...

Capricor Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its deramiocel cell therapy for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The agency...

Biopharma dealmaking hit a record $35 billion in June 2025, marking the highest monthly total of the year and bolstering H1 figures to $138 billion, surpassing full-year totals from pre-2020...